NCT04861207View on ClinicalTrials.gov

Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 7, 2021

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Acute Myeloid Leukemia Myelodysplastic Syndromes
Interventions
DRUG

Cladribine

The conditioning regimen used will be cladribine-based at a dose of 5 mg / m2 for 5 days (iv.) and total body irradiation at a total dose of 12 Gy in three fractions.

Trial Locations (1)

44-101

Klinika Transplantacji Szpiku i Onkohematologii Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Oddział w Gliwicach, Gliwice

Sponsors

Collaborators (1)

KCRI
All Listed Sponsors
collaborator

KCRI

OTHER

lead

Maria Sklodowska-Curie National Research Institute of Oncology

OTHER

NCT04861207 - Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter